A physical performance measure for individuals with mucopolysaccharidosis type I

被引:18
|
作者
Haley, Stephen M.
Pinkham, Maria A. Fragala
Dumas, Helene M.
Ni, Pengsheng
Skrinar, Alison M.
Cox, Gerald F.
机构
[1] Boston Univ, Hlth & Disabil Res Inst, Boston, MA 02215 USA
[2] Genzyme Corp, Clin Res, Cambridge, MA USA
来源
关键词
D O I
10.1017/S0012162206001216
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The purpose of this article is threefold: (1) to describe the development, reliability, and validity of a revised physical performance measure for individuals with mucopolysaccharidosis type I (MPS 1); (2) to standardize the test on a normal sample; and (3) to compare results from a selected sample of individuals with MPS I with age-based centiles. The MPS Physical Performance Measure (MPS-PPM) is composed of eight timed functional tasks (FT-8) and two endurance tasks with a modified Energy Expenditure Index for comfortable walking (CW) and fast walking (FW) speeds. Age norms were derived from a convenience sample of 150 typically developing children and adolescents (75 males, 75 females; mean age 11y 2mo, [SD 4y 5mo]; range 5-22y). Using a Rasch model for speed tests and confirmatory factor analysis, we established the unidimensionality of the FT-S. Interrater reliability of the FT-8 (intraclass correlation [ICC]=0.98) and test-retest reliability of the FT-8 (ICC=0.96), CW (ICC=0.91), and FW (ICC=0.83) were good. Results of the age-based profiles in 10 individuals with MPS I (five males, five females; mean age 14y 2mo [SD 7y 6mo]; range 6-29y) indicate that the amount of time needed to perform functional tasks is severely affected by the disease, and most individuals were at or below the fifth centile for their age. The patterns of limitations in endurance were more varied. These results suggest the utility of using this revised MPS-PPM to identify the extent of limitation in age-expected physical performance. Implications for using the MPS-PPM for monitoring physical performance changes during clinical interventions are discussed.
引用
收藏
页码:576 / 581
页数:6
相关论文
共 50 条
  • [21] Glycosaminoglycans as anticoagulants in mucopolysaccharidosis type I (MPS I)
    Tolar, Jakub
    Orchard, Paul J.
    Key, Nigel
    Blazar, Bruce R.
    BLOOD, 2007, 110 (11) : 55B - 55B
  • [22] Growth in individuals with attenuated mucopolysaccharidosis type I during untreated and treated periods: Data from the MPS I registry
    Polgreen, Lynda E.
    Bay, Luisa
    Clarke, Lorne A.
    Guffon, Nathalie
    Jones, Simon A.
    Muenzer, Joseph
    Flores, Ana Lorena
    Wilson, Kathryn
    Viskochil, David
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2022, 188 (10) : 2941 - 2951
  • [23] Circulating anticoagulant glycosaminoglycans in mucopolysaccharidosis type I
    Tolar, J.
    Orchard, P. J.
    Key, N. S.
    Blazar, B. R.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (05) : 893 - 895
  • [24] Diagnostic strategy of mucopolysaccharidosis type I in Tunisia
    Chkioua, L.
    Ferchichi, S.
    Khedhiri, S.
    Laradi, S.
    Bibi, A.
    Amira, D.
    Dandana, A.
    Ben Mansour, R.
    Ben Limam, H.
    Chaabouni, M.
    Froissart, R.
    Maire, I.
    Miled, A.
    ANNALES DE BIOLOGIE CLINIQUE, 2007, 65 (02) : 175 - 179
  • [25] The potential of gene therapy for mucopolysaccharidosis type I
    Pimentel Vera, Luisa Natalia
    Baldo, Guilherme
    EXPERT OPINION ON ORPHAN DRUGS, 2020, 8 (01): : 33 - 41
  • [26] Management of aortic stenosis in mucopolysaccharidosis type I
    Felice, Tiziana
    Murphy, Elaine
    Mullen, Michael J.
    Elliott, Perry M.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 172 (03) : E430 - E431
  • [27] Diagnosis, classification and treatment of mucopolysaccharidosis type I
    Langereis, Eveline J.
    van Vlies, Naomi
    Wijburg, Frits A.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (03): : 307 - 320
  • [28] Consensus on Mucopolysaccharidosis Type I diagnosis and treatment
    Bay, Luisa
    ARCHIVOS ARGENTINOS DE PEDIATRIA, 2008, 106 (04): : 361 - 368
  • [29] Enzyme replacement therapy in mucopolysaccharidosis type I
    Miebach, E
    ACTA PAEDIATRICA, 2005, 94 : 58 - 60
  • [30] Mild forms of mucopolysaccharidosis type I (MPSI)
    Vashakmadze, Nato
    Zhurkova, Natalya
    Zakharova, Ekaterina
    Babaikina, Marina
    Rykunova, Anastasia
    Namazova-Baranova, Leyla
    MOLECULAR GENETICS AND METABOLISM, 2021, 132 (02) : S108 - S108